Table 1.
Descriptive statistics of Swedish patients and tumor sets.
| Characteristics | Patient % (count) |
|---|---|
| PATIENTS | |
| Age | |
| Mean age (years) | |
| 67.4 | |
| Range (years) | |
| 43–96 | |
| Group | |
| < 70 years | 62% (38) |
| > 70 years | 38% (23) |
| Ancestry | |
| European | 100% (61) |
| Site | |
| Primary | 100%(61) |
| Treatment | |
| No neoadjuvant | 100%/61) |
| TUMORS | |
| Hormone-receptor | |
| ER + | 85% (52) |
| PR + | 77% (47) |
| HER2 + | 11%(7) |
| ER + /PR + | 66% (40) |
| ER-/PR-/HER2- | 3% (2) |
| Histopathology | |
| Lobular | 7% (4) |
| Ductal | 92% (56) |
| Ductal-in situ | 13% (8) |
| Tumor fraction | |
| < 50% | 18% (11) |
| 51–60% | 30% (18) |
| 61–70% | 22% (14) |
| 71–85% | 30% (18) |
ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor 2.